KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024年4月2日 - 7:30PM
ビジネスワイヤ(英語)
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
that the compensation committee of KalVista’s board of directors
granted nine newly-hired employees inducement options to purchase
an aggregate of 65,000 shares of KalVista common stock on April 1,
2024 as inducements material to each employee entering into
employment with KalVista. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $11.40 per share, which
was equal to the closing price of KalVista common stock on the
grant date. One-fourth of the options vest on the one-year
anniversary of the vesting commencement date and the remainder vest
in equal monthly installments over the next three years, in each
case subject to the new employee’s continued service with the
company. Each stock option has a 10-year term and is subject to the
terms and conditions of KalVista’s Inducement Equity Incentive Plan
and a stock option agreement covering the grant.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista disclosed positive phase 3 data
for the KONFIDENT trial for its oral, on-demand therapy
sebetralstat in February 2024. The Company anticipates submitting a
new drug application to the U.S. FDA for sebetralstat in the first
half of 2024 and expects to file for approval in Europe and Japan
later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor
program represents a new generation of therapies that may further
improve the treatment for people living with HAE and other
diseases.
For more information about KalVista, please visit
www.kalvista.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240402778985/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
過去 株価チャート
から 4 2024 まで 5 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
過去 株価チャート
から 5 2023 まで 5 2024